696 related articles for article (PubMed ID: 26428381)
1. Immune Evasion by Epstein-Barr Virus.
Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
3. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
4. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
6. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
7. The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.
Gram AM; Oosenbrug T; Lindenbergh MF; Büll C; Comvalius A; Dickson KJ; Wiegant J; Vrolijk H; Lebbink RJ; Wolterbeek R; Adema GJ; Griffioen M; Heemskerk MH; Tscharke DC; Hutt-Fletcher LM; Wiertz EJ; Hoeben RC; Ressing ME
PLoS Pathog; 2016 Apr; 12(4):e1005550. PubMed ID: 27077376
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
[TBL] [Abstract][Full Text] [Related]
10. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
11. Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus.
Bouvet M; Voigt S; Tagawa T; Albanese M; Chen YA; Chen Y; Fachko DN; Pich D; Göbel C; Skalsky RL; Hammerschmidt W
mBio; 2021 Mar; 12(2):. PubMed ID: 33785626
[TBL] [Abstract][Full Text] [Related]
12. EBV-Specific Immune Response: Early Research and Personal Reminiscences.
Moss DJ; Lutzky VP
Curr Top Microbiol Immunol; 2015; 390(Pt 1):23-42. PubMed ID: 26424642
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
14. [Regulation and evasion of host immune responses by Epstein-Barr virus].
Xiao N; Chen Q; Cai S
Wei Sheng Wu Xue Bao; 2016 Jan; 56(1):19-25. PubMed ID: 27305776
[TBL] [Abstract][Full Text] [Related]
15. Contrasting roles of dendritic cells and B cells in the immune control of Epstein-Barr virus.
Bickham K; Münz C
Curr Top Microbiol Immunol; 2003; 276():55-76. PubMed ID: 12797443
[TBL] [Abstract][Full Text] [Related]
16. Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion.
van Gent M; Gram AM; Boer IGJ; Geerdink RJ; Lindenbergh MFS; Lebbink RJ; Wiertz EJ; Ressing ME
J Gen Virol; 2015 Apr; 96(Pt 4):858-865. PubMed ID: 25502648
[TBL] [Abstract][Full Text] [Related]
17. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses.
Wang M; Yu F; Wu W; Wang Y; Ding H; Qian L
Int J Biol Sci; 2018; 14(5):565-576. PubMed ID: 29805308
[TBL] [Abstract][Full Text] [Related]
20. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
Mautner J; Bornkamm GW
Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
